Eos Energy stock falls after Fuzzy Panda issues short report
LONDON - Tissue Regenix Group plc (AIM:TRX), a regenerative medical devices company, announced Wednesday it has rescheduled the release of its interim financial results to Tuesday, September 30.
The company had previously communicated its reporting timeline on September 8, according to the statement.
Chief Executive Officer Daniel Lee and Executive Chairman Jay LeCoque will host a live online presentation discussing the interim results via the Investor Meet Company platform at 4pm BST on September 30. The presentation will be accessible to both existing and potential shareholders.
Tissue Regenix specializes in regenerative medicine, utilizing its proprietary decellularisation technology (dCELL®) that removes DNA and cellular material from animal and human soft tissue. This process creates acellular tissue scaffolds that can be used in medical applications without triggering rejection by the patient’s body.
The company’s current product applications focus on sports medicine, foot and ankle injuries, and wound care treatments.
Cavendish Capital Markets Limited serves as the nominated adviser and broker for Tissue Regenix.
This announcement was made through a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.